NASDAQ:AEGR - Aegerion Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$1.97
Today's RangeN/A
52-Week Range$1.23 - $10.85
VolumeN/A
Average Volume635,262 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).

Receive AEGR News and Ratings via Email

Sign-up to receive the latest news and ratings for AEGR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:AEGR
CUSIP00767E10
Phone+1-617-5007867

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees318
Next Earnings DateN/A
OptionableNot Optionable

Aegerion Pharmaceuticals (NASDAQ:AEGR) Frequently Asked Questions

What is Aegerion Pharmaceuticals' stock symbol?

Aegerion Pharmaceuticals trades on the NASDAQ under the ticker symbol "AEGR."

How were Aegerion Pharmaceuticals' earnings last quarter?

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) issued its quarterly earnings data on Monday, May, 16th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.58) by $1.14. The biopharmaceutical company had revenue of $35.70 million for the quarter, compared to analyst estimates of $43 million. The company's revenue was down 39.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.55) EPS. View Aegerion Pharmaceuticals' Earnings History.

Has Aegerion Pharmaceuticals been receiving favorable news coverage?

Press coverage about AEGR stock has trended somewhat positive on Thursday, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aegerion Pharmaceuticals earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the immediate future.

How do I buy shares of Aegerion Pharmaceuticals?

Shares of AEGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aegerion Pharmaceuticals' official website?

The official website for Aegerion Pharmaceuticals is http://www.aegerion.com.

How can I contact Aegerion Pharmaceuticals?

Aegerion Pharmaceuticals' mailing address is 1 Main St Ste 800, CAMBRIDGE, MA 02142-1531, United States. The biopharmaceutical company can be reached via phone at +1-617-5007867.


MarketBeat Community Rating for Aegerion Pharmaceuticals (NASDAQ AEGR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  344 (Vote Outperform)
Underperform Votes:  277 (Vote Underperform)
Total Votes:  621
MarketBeat's community ratings are surveys of what our community members think about Aegerion Pharmaceuticals and other stocks. Vote "Outperform" if you believe AEGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel